Hello, everyone, and how are you today? Cloudy skies are hovering over the Pharmalot corporate campus, but our spirits are sunny. You know the mantra from the Morning Mayor: Every brand new day should be unwrapped like a precious gift. So go ahead and tug on the ribbon. While you do, we will brew another needed cup of stimulation and prepare for another busy day. We know you can relate - meetings and deadlines await. Here are some interesting items to get you started. Have a great day...
Genzyme Recalls Leukemia Drug Made At Ben Venue Plant (Bloomberg News)
Hospitals Toss Scarce Drugs Due To Rules (MSNBC)
NICE To Allergan: More Evidence Needed For Botox For Migraines (Bloomberg News)
Sandoz Buys German Rights To Apricus Sex Drug (Reuters)
Reed Elsevier Adds AstraZeneca CEO David Brennan As A Director (MarketWatch)
GlaxoSmithKline Faces Opposition In Scotland To Wind Turbines (The Courier)
FDA OKs GenProbe Test For Prostate Cancer Risk (Xconomy)
Pfizer Claims $960M In Damages From Sun Pharma Over Protonix Patent (Economic Times)
Merck Creates Joint Venture In Brazil (Associated Press)
Harvard AIDS Coalition Protests Merck HIV Drug Pricing (Harvard Crimson)
Novartis Boosts Investment In Taiwan (CENS)
EDITOR'S NOTE: Please check this post for updates throughout the morning
steaming coffee thx to dleggett on flickr
2 Comments
Those Harvard AIDS folks should thank their lucky stars for companies like Merck instead of ripping them. If it wasn't for Merck having the first protease inhibitor (Crixivan, 1996) who knows how long the entire therapeutic category might have been delayed.
G'morning, Ed!
Interesting article from Forbes on big pharma: http://www.forbes.com/sites/aroy/2012/02/15/how-big-pharmaundermined-medical-innovation-for-financial-gain/?partner=yahoofeed